From Pilot to Portfolio: Scaling Circular Packaging
Find the authors
on LinkedIn:

From Pilot to Portfolio: Scaling Circular Packaging

We have seen plenty of circular packaging pilots that work in isolation.

A new design that’s more recyclable. An increase in recycled content. A workable deposit return trial that performs well in-store. A positive refill system experiment with a strong story behind it.

Then they stall

Not because the intent was wrong, but because pilots sit outside the full operating system and true commercial pressures. They are rightly protected from the cost, infrastructure, and commercial realities to test and learn consumer behavior, but are often ill-equipped to adapt for scale.

That is why packaging Extended Producer Responsibility (EPR) matters, as this is a scale-centric challenge.

It shifts packaging from a waste topic to a design and business topic. The Organisation for Economic Co-operation and Development (OECD), describes EPR as a policy approach that makes producers responsible through the post-consumer stage, while also generating funding and information for collection, sorting, and recycling systems. And the policy context is no longer theoretical. In the EU, the PPWR entered into force on February 11, 2025, and generally applies from August 12, 2026. In the UK, obligated producers must register, report packaging data, and pay fees. Australia is reforming packaging regulation to align packaging with circular economy principles. Ontario completed its transition to full producer responsibility on January 1, 2026. Canada expects packaging EPR for packaging in most, if not all, provinces and territories by 2030.

So the question is no longer whether circular packaging should be scaled.

The more useful question is this: will compliance effort be treated as a cost of doing business, or used as a lens for sharper portfolio choices?

Because as EPR becomes a reality, companies are forced to define things that pilots can leave vague or don’t answer. Which end-of-life pathway is realistic in each market? How likely is collection and effective sorting in normal conditions? Where is packaging complexity creating cost without improving recovery? Those are not paperwork questions. They are design questions, procurement questions, and portfolio questions. This is why EPR is better understood as a portfolio lens than a pilot trigger. Pilots still matter. They are often essential for testing formats, claims, and consumer participation models. But pilots alone do not tell you how a portfolio performs across geographies, channels, suppliers, materials, and recovery systems. That wider view is where scale is won or lost.

Pilots often succeed because they benefit from exceptional conditions. One geography. One retail partner. One highly engaged consumer group. One supplier willing to stretch. One team willing to intervene when reality gets messy. In some cases, even supportive national policy environments, such as France’s emerging regulatory push on reuse and refill under its circular economy legislation, can effectively act as a scaled, semi-controlled test bed.

Portfolios operate under normal conditions. They carry multiple markets, multiple channels, multiple suppliers, competing cost pressures, and uneven infrastructure. At that scale, the test is not whether a packaging idea worked once. The test is whether it still works when it becomes business as usual.

EPR also brings consumer behavior into focus. Packaging systems only work when people can participate in them. If organizations say they are consumer-centered, this is where that claim has to show up. Legislation should be used not just to meet regulatory requirements, but to design packaging experiences that are intuitive, low-friction, and aligned with everyday behavior. Disposal instructions need to be clear. Return and refill participation needs to feel intuitive. Sorting needs to work in ordinary households, not just in ideal conditions. Get this right, and you improve more than recovery. You reduce contamination, lower fee exposure, and strengthen the overall product experience.  Regulations will then not only encourage circularity, but they create a purposeful moment of action and innovation for companies to strengthen brand trust, delivering tangible value to consumers as well as the business. In other words, EPR can turn circularity from a pilot activity into an operating model that also improves the consumers’ experience, if companies use the opportunity.

Circularity has always been a system design challenge, and EPR is accelerating this advancement. The task is not simply to improve one pack in isolation. It is to understand how material choice, format, infrastructure compatibility, consumer participation, evidence burden, fee exposure, and end market reality interact. That is a different level of discipline, and it tends to expose weaknesses quickly.

A portfolio view allows better questions. Which formats create the highest compliance and cost exposure? Which packs have the weakest real-world recovery pathway? Which material choices add complexity without improving the outcome? Where can harmonization reduce cost and improve recyclability? Which claims are robust, and which are vulnerable? Where could redesign create both environmental gain and economic value?

The strongest companies will not treat EPR as a layer of administration added to yesterday’s packaging choices. They will use it to redesign how those choices are made. In practice, that means defining end-of-life pathways in operational terms, separating what can be standardized globally from what must be adapted locally, evaluating packs with a balanced scorecard rather than a single metric, testing behavior honestly, building the evidence plan early, and staging change across the portfolio where learning is fastest and risk is lowest.

Handled tactically, EPR will bring short-term pain with few long-term gains. Handled strategically, it should shape and accelerate the decisions you ultimately need to make to protect your future.

As part of a strategy, it can become a source of commercial advantage. Not because regulation is inherently beneficial to producers. It is not. But because it can force the level of scrutiny, many organizations have postponed. That scrutiny can lead to fewer problematic formats, better alignment between design and infrastructure, lower material intensity, stronger claims, smarter use of recycled content, and clearer investment cases for reuse, refill, or redesign where those moves are genuinely viable.

The companies most likely to create value from packaging EPR will be the ones that use that pressure to review the portfolio properly and scale the changes that actually work.

At Cambridge Design Partnership, we help teams translate regulatory changes to practical design and engineering action. That means identifying where recovery pathways are weak, where behavioral assumptions are unrealistic, where evidence requirements need to shape the brief earlier, and where material and format decisions are creating hidden risk. Typically, that means combining circular diagnostic work, sustainability screening, Sustainability Clean sheeting, human-centered design, engineering validation, and regulatory readiness into a single decision process.

It’s worth asking one final question. Are you only preparing to comply, or are you using this moment to reshape the portfolio for a more circular and commercially resilient future?

 

A,Person,Holds,Several,Packs,Of,Pills,Over,A,Yellow
Find the authors
on LinkedIn:

Sustainable pharmaceutical packaging without compromising safety or usability

When people talk about “sustainable packaging,” they often picture quick material swaps and bold recyclability claims. But in pharmaceuticals, it’s rarely that simple.

Pharma packaging is a safety-critical system. It protects sensitive formulations, supports regulatory compliance, and helps patients take the right medicine in the right way, every time.

That’s why packaging teams are under a different kind of pressure: they are being asked to reduce environmental impact while holding the line on performance, patient safety, and supply resilience.

At Cambridge Design Partnership (CDP), we work with pharma and healthcare teams to make that trade space manageable. The goal isn’t sustainability as a side project. It’s packaging decisions that are evidence-led, patient-centered, and durable under regulatory scrutiny.

The structural tension at the heart of pharmaceutical packaging

In practice, pharmaceutical packaging exists inside tight constraints that are in place for good reason:

  • Validated moisture, oxygen, and light barriers (often with narrow stability margins)
  • Strict control of chemical interactions and leachables across materials, inks, adhesives, and coatings
  • Tamper evidence, traceability, and serialization requirements
  • Repeatable, audited manufacturing processes with controlled change management
  • Global regulatory alignment, long shelf-life assurance, long qualification cycles, and post-approval variation burden

However, here is another non-negotiable that is often underweighted in sustainability conversations: patient usability.

In effect, packaging is the interface between medicine and the person using it. It must enable patients to identify the correct drug clearly, complete any necessary inspection (for example, tamper evidence, integrity, or visual checks, where relevant), and access the drug product reliably. If a sustainability change makes a pack harder to open, harder to read, or easier to confuse, it creates a risk that overwhelms the environmental benefit.

As a result, progress is rarely about a single material substitution. Sustainable outcomes come from system decisions – barrier, labeling, usability, manufacturing, logistics, and end-of-life considered together.

Why the pressure is now unavoidable

1. Regulation is becoming a market access issue.

In Europe, the PPWR (Packaging and Packaging Waste Regulation) is now the anchor regime: it entered into force in February 2025 and will apply from August 2026, with recyclability tightening through 2030 and a formal review horizon in 2035 that is explicitly relevant to certain pharma pack exemptions. Here, the key challenge is timing: regulatory clocks move faster than pharma packaging platforms can change.

2. Stakeholder expectations are rising.

At the same time, payers, providers, investors, and patients increasingly expect credible action. Packaging is visible, measurable, and easy to compare – so it’s becoming a practical test of seriousness, not a marketing footnote.

3. The business case is shifting from “nice to have” to “must manage”.

Consequently, packaging decisions now touch cost, resilience, and speed to market: material exposure, waste fees, supply fragility, and late-stage redesign risk. In most cases, getting ahead of change is usually cheaper than reacting when options are already locked.

What we see in real programs

A few patterns show up repeatedly when teams try to move from intent to execution.

The biggest wins aren’t always in the primary pack.
In many cases, primary packaging can be the hardest part of the system to change quickly. By contrast, secondary and tertiary packaging (such as cartons, leaflets, protective elements, and shipping formats) often provide faster, lower-risk opportunities – especially when you design them to reduce total material use, improve transport efficiency, and avoid formats that create sorting and recycling problems.

“Recyclable” is not the same as “safe, compliant, and used correctly.”
For pharma, the right question is usually: What is the lowest-impact design that still delivers stability, compliance, and patient usability? That framing prevents false optimization.

Late redesign is the hidden cost.
When sustainability is added after packaging architecture decisions are made, you end up negotiating against a nearly fixed design. That’s when cost and time blow out – and when risk rises.

A practical framework for executive decision-making

If you’re leading packaging strategy, the most useful step is to turn sustainability into a structured decision process rather than a series of ad hoc requests. Here’s a framework we use with teams to keep work focused and defensible.

1. Define your non-negotiables up front

  • Before exploring options, align on what cannot be compromised:
  • Patient safety and correct use
  • Readability and differentiation (right medicine, strength, dose, expiration)
  • Access and openability under real-world conditions
  • Barrier performance and shelf-life confidence
  • Tamper evidence and traceability requirements
  • Validated manufacturing performance and supply resilience

This avoids “optimizing” a pack into something that fails in the field.

2. Establish a credible baseline, quickly

You don’t need a year-long study to find direction. A focused baseline – material flows, key pack components, manufacturing yield sensitivity, logistics assumptions, and end-of-life reality – usually reveals where the impact sits and where it doesn’t.

This is where we often apply lifecycle thinking and our Sustainability Cleansheet method: Quantify the big cost and environmental impact drivers early so you don’t spend months improving the wrong thing.

3. Build a short list of options and stress-test the tradeoffs

For each option, teams should be able to answer clearly:

  • What changes physically? (materials, structure, labels, coatings, inks, adhesives)
  • What risks move? (stability margin, E&L, usability, line performance, supply continuity)
  • What improves? (impact reduction, cost, simplification, waste reduction, data/traceability)
  • What evidence is needed? (bench tests, line trials, stability, human factors validation)

The aim is not perfect certainty. It’s the early elimination of weak options and disciplined focus on the few options that can scale.

4. Pilot to reduce uncertainty, not to signal virtue

In pharma, pilots only matter if they answer hard questions: manufacturability, patient behavior, stability confidence, and real end-of-life outcomes (not just theoretical recyclability).

We design pilots to generate decision-grade evidence, so teams can commit without gambling.

5. Use “smart print” technologies thoughtfully

Many teams want digital capability – traceability, anti-counterfeit protection, patient guidance, or better sorting instructions – without turning packaging into electronics.

That’s where smart print technologies can help: Printed features (from advanced QR codes and variable data to printed conductive inks and thin printed circuits) can deliver “DPP-style” benefits – linking the pack to verified product data, instructions, and chain-of-custody information – without adding bulky components.

But they still require end-of-life thinking. Even small amounts of conductive ink or functional layers can affect recycling behavior and material recovery if they’re used indiscriminately. The practical approach is:

  • Keep digital features as light as possible (often secondary packaging is the right home)
  • Avoid designs that contaminate or complicate recycling streams
  • Choose materials and inks with recovery pathways, where available
  • Be explicit about the end-of-life intent, not just the in-use feature set

Smart features can support compliance and patient outcomes – but only if they’re designed as part of the packaging system, not bolted on.

6. Build a roadmap that matches pharma timelines

Packaging change in pharma is slow by design: qualification, validation, supplier readiness, and stability programs all take time. That’s exactly why the gap between product development cycles and regulatory timelines matters. The right roadmap staggers effort:

  • Near term: Secondary and tertiary improvements and material reduction
  • Mid term: Architecture changes where stability risk is manageable
  • Long term: Platform shifts and primary packaging strategies aligned to the next regulatory horizon

How CDP helps

Clients bring us in when they need momentum without compromising on safety. What makes CDP different is the way we connect the disciplines that usually sit apart:

The result is packaging strategy that holds up: Lower-impact solutions that are still manufacturable, compliant, and usable – built on evidence rather than hope.

The opportunity

Sustainable pharmaceutical packaging isn’t about copying approaches from consumer goods. It’s about designing within the constraints that matter – stability, safety, usability, and supply assurance – while still making real progress on impact.

If you’re responsible for packaging strategy and you’re facing tighter timelines, rising expectations, and harder tradeoffs, we can help you move faster with confidence.

Connect with CDP

For more on how to accelerate meaningful innovation in sustainable pharmaceutical packaging, contact Cambridge Design Partnership.

graphics_hero_dd-to-the-brain
Find the authors
on LinkedIn:

Drug Delivery to the Brain: Engineering Precision Across Novel Modalities

graphics_web-body_featured-in-podd-logo

Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), motor neuron disease (MND, including amyotrophic lateral sclerosis, (ALS)), and frontotemporal dementia (FTD) remain areas with limited disease-modifying treatments. Therapeutic pipelines in this area are increasingly dominated by antisense oligonucleotides (ASOs), RNA interference (RNAi) molecules, monoclonal antibodies, and viral gene therapies such as adeno-associated virus (AAV). These modalities offer the potential to modulate genetic pathways, reduce toxic proteins, or deliver genes to modulate disease pathways.

However, the size, structure, and physicochemical properties of these modalities largely prevent them from crossing the blood–brain barrier (BBB) through systemic delivery routes. The brain’s protective architecture restricts where and how these molecules can be delivered, and their complexity introduces delivery demands that conventional administration cannot meet.

Drug development must therefore evolve in parallel with delivery system design.

Once a modality is defined, the delivery strategy and device architecture required to administer it safely, precisely and effectively must be developed alongside it.

Why New Modalities Require Bespoke Approach to Delivery

Many of the emerging central nervous system (CNS) modalities have delivery requirements that differ fundamentally from traditional therapeutics. ASOs and RNAi therapeutics, for example, require broad CNS exposure and are therefore commonly administered into the cerebrospinal fluid (CSF) rather than via more localised, parenchymal approaches. CSF flow is largely pulsatile and oscillatory, with a slow net movement along the spine. After lumbar intrathecal administration, for example, these transport dynamics together with limited diffusion and tissue uptake, usually cause the drug to stay concentrated near the injection site and to decrease progressively as it travels upward towards the brain. Because these molecules are highly charged and diffuse slowly, such gradients persist, limiting penetration into deep structures without controlled flow. Device requirements should therefore include precise catheter placement, controlled infusion, prevention of local pooling, and repeat dosing capability.

In contrast, large proteins such as monoclonal antibodies must reach cortical, subcortical, or deep-brain regions, necessitating intracerebroventricular or intraparenchymal delivery. Devices must incorporate many elements to ensure targeted delivery such as reflux-resistant geometries, strategies for targeted spatial coverage, controlled infusion profiles, and low-adsorption materials to prevent protein aggregation.

Viral gene therapies impose some of the strictest demands on delivery systems. AAV vectors are sensitive to shear forces, turbulence, surface adsorption, and pressure changes, and maintaining capsid integrity throughout preparation and infusion is critical. Delivery systems must include ultra-smooth internal surfaces, gentle and stable low flow rates, inert materials, and high-precision targeting of deep structures.

In these cases, the delivery device becomes an integral component of the therapeutic product.

Device Engineering as a Core Component of Drug Development

When delivery impacts therapeutic efficacy, the device effectively becomes part of the therapy. The mechanical, geometric, and material requirements of a delivery system must therefore be defined not only by clinical considerations, but by the physical and biological behaviour of the therapeutic agent and the tissue it enters. In the CNS, this means accounting for the poroelastic nature of brain tissue, how it deforms, absorbs, dissipates, and redistributes fluid under pressure. These properties vary markedly between grey and white matter, differ across deep nuclei and cortical layers, and evolve dynamically as disease alters cellular composition, extracellular matrix structure, and hydraulic resistance. Such heterogeneity means that a device designed for one anatomical context may not perform predictably in another, even at identical infusion parameters.

Because these biological factors directly shape how infusate spreads, engineers must design delivery systems around the interplay between modality constraints and tissue mechanics. This shifts the focus from simply handling the molecule to engineering the conditions under which it travels. Cannula-based systems, for example, are one way of addressing this focus and key decisions include selecting tip geometries that balance mechanical stability with minimal insertion trauma; choosing port architectures that control local flow vectors and prevent jetting or backflow; and tuning lumen dimensions and surface properties to reduce adsorption, shear-induced degradation, or clogging under clinically relevant conditions. Each of these choices dictates how the therapeutic is introduced into the tissue microenvironment and how reliably it follows intended distribution pathways.

Beyond the insertion device itself, infusion strategy becomes a critical engineering parameter in its own right. Flow rate, pressure control, and infusion timing must be optimised to avoid exceeding the tissue’s capacity to deform safely, a threshold that varies with pathology, age, and regional structure. In some contexts, a constant-pressure approach stabilises the infusion front, while in others, constant-flow allows more predictable volumetric spread. Incorporating features such as pressure-relief paths, multiport configurations, or dynamic flow modulation can further tailor distribution when a single port or monotonous flow profile is insufficient. The device, in other words, does not merely deliver the therapy, it shapes how the therapy propagates through complex biological substrates.

Thus, the therapeutic modality defines the device’s safe and effective operating window, from acceptable flow ranges to port geometry and infusion timing.

Integrating these constraints into device architecture is what converts a therapeutic concept into a deliverable intervention, shaping dosing, distribution, and clinical performance. This perspective anchors the subsequent design decisions and highlights why device engineering must evolve in parallel with emerging therapeutic modalities.

Research and Modelling: Validating Drug–Device Interaction

Ensuring a therapy reaches the right place (and not off-target), in the right amount, requires evidence. That evidence comes from a spectrum of approaches. In-silico modelling is often the first step, using first-principles physics, computational fluid dynamics, or finite-element methods to explore how a device, a therapeutic, and the brain’s microstructure interact. These models account for tissue porosity, elasticity, white–grey matter boundaries, fluids viscosity and dynamics, and pressure gradients to forecast how an infusion will spread before a single experiment is run.

But simulations are only as good as the worlds we build for them. Brain-mimicking hydrogels and 3D-printed phantoms provide physical testbeds where model-based predictions are challenged and refined. They make flow visible, enable rapid parameter testing, and allow researchers to probe failure modes without the constraints of animal work. These platforms narrow uncertainty and help translate computational insights into practical infusion parameters, helping guide device design.

Animal studies deliver the critical translational step, revealing how elements such as distribution, tissue response, device–tissue mechanics, and (for gene therapies) transgene expression play out in vivo. Here, the goal is not just to confirm spread, but to understand how biology responds to the physical act of delivery, a dimension no model or phantom can fully capture.

Together, these stages form an iterative design–test–refine loop, which is essential for reliable, modality-specific CNS delivery.

Collaborative Expertise and Scientific Frameworks

Because device-based delivery is integral to being able to achieve therapeutic effect of these modalities, progress depends on teams that can bridge biology, engineering, modelling, and clinical practice. Each discipline contributes a different piece: drug discovery teams define the therapeutic goal and target exposure; engineers translate those needs into device and flow-system architectures; modellers anticipate how an infusion will behave in complex tissue or fluid; neurosurgeons test procedural feasibility and targeting; imaging specialists verify where the therapy actually goes; and human factors experts ensure the device can be used safely and reliably in real clinical settings. Innovation emerges at the intersections of these disciplines, where insights are shared and refined.

To support this, many organisations draw on multidisciplinary scientific advisory boards (SABs) that span neurodegeneration, biomaterials, computational modelling, device engineering, neurosurgery, and regulatory science.

These boards provide an early-warning system for delivery challenges, shaping designs and validation strategies and ensuring that device performance stays aligned with biological and clinical requirements.

Complementing this are pre-competitive collaborations, modelling consortia, shared phantom libraries, device-testing networks, and harmonised imaging datasets, that give teams a common scientific language. These shared resources reduce duplication, improve reliability, and accelerate the path from concept to clinically deployable delivery systems.

Conclusion

Novel modalities, including ASOs, RNAi agents, antibodies, and viral gene therapies, represent the leading edge of neurodegenerative therapeutic innovation. But realising their full potential depends on delivery systems that are precise, reliable, and tailored to each modality’s unique demands.

Device design and engineering must therefore advance in parallel with drug development, supported by rigorous modelling, interdisciplinary expertise, and integrated scientific frameworks. By uniting therapeutic design with delivery system innovation, the field is laying the groundwork for meaningful progress in neurodegenerative diseases and accelerating the pace of CNS therapeutic innovation.

References

    1. Yang HM. Overcoming the Blood-Brain Barrier: Advanced Strategies in Targeted Drug Delivery for Neurodegenerative Diseases. Pharmaceutics. 2025 Aug 11;17(8):1041. doi: 10.3390/pharmaceutics17081041. PMID: 40871062; PMCID: PMC12388969.

    1. Gao J, Gunasekar S, Xia ZJ, Shalin K, Jiang C, Chen H, Lee D, Lee S, Pisal ND, Luo JN, Griciuc A, Karp JM, Tanzi R, Joshi N. Gene therapy for CNS disorders: modalities, delivery and translational challenges. Nat Rev Neurosci. 2024 Aug;25(8):553-572. doi: 10.1038/s41583-024-00829-7. Epub 2024 Jun 19. PMID: 38898231.

    1. Wu, D., Chen, Q., Chen, X. et al. The blood–brain barrier: Structure, regulation and drug delivery. Sig Transduct Target Ther 8, 217 (2023). https://doi.org/10.1038/s41392-023-01481-w

    1. Hunt MA, Hunt SAC, Edinger K, Steinauer J, Yaksh TL. Refinement of intrathecal catheter design to enhance neuraxial distribution. J Neurosci Methods. 2024 Feb;402:110006. doi: 10.1016/j.jneumeth.2023.110006. Epub 2023 Nov 13. PMID: 37967672.

    1. Yuan T, Zhan W, Terzano M, Holzapfel GA, Dini D. A comprehensive review on modeling aspects of infusion-based drug delivery in the brain. Acta Biomaterialia. 2024 Sep 1;185:1-23.

    1. Lonser RR, Sarntinoranont M, Morrison PF, Oldfield EH. Convection-enhanced delivery to the central nervous system. J Neurosurg. 2015 Mar;122(3):697-706. doi: 10.3171/2014.10.JNS14229. Epub 2014 Nov 14. PMID: 25397365.

Connect with CDP

For more on how to accelerate meaningful innovation in drug delivery, contact Cambridge Design Partnership.